Scott So, MD
Ophthalmology · San Francisco, CANPI 1942229984
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $133,051 of the $173,367 with a category attached, or 76.7%. AbbVie accounts for 89.0% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2022 at $50,681 and has fallen 84.4% since, to $7,920 in 2025. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 736 payments — averaging $235.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$154K
- Aerie Pharmaceuticals, Inc.$6K
- Alcon$2K
- Kala Pharmaceuticals, Inc.$2K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
- Novartis$2K
- plus $6K from 23 others
Across 106 payments — averaging $1734.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$178K
- Johnson & Johnson Surgical Vision, Inc.$6K
What the payments were for
- Consulting fees$12,8087%
- Speaking & faculty fees$133,05177%
- Travel & lodging$6,8984%
- Food & beverage$19,11711%
- Education$360%
- Gifts$450%
- Other$1,4131%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 403 | $154,244 |
| Aerie Pharmaceuticals, Inc. | 41 | $6,093 |
| Alcon | 62 | $1,952 |
| Kala Pharmaceuticals, Inc. | 10 | $1,869 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 24 | $1,694 |
| Novartis | 68 | $1,556 |
| Carl Zeiss Meditec USA, Inc. | 3 | $1,442 |
| Bausch & Lomb Americas Inc. | 35 | $721 |
| Sight Sciences, Inc. | 18 | $665 |
| Glaukos Corporation | 3 | $415 |
| Oyster Point Pharma, Inc. | 10 | $391 |
| Thea Pharma Inc. | 4 | $327 |
| Biotissue Holdings Inc. | 9 | $300 |
| Astellas Pharma US Inc | 8 | $266 |
| Rxsight Inc | 6 | $243 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $219 |
| Apellis Pharmaceuticals, Inc. | 5 | $219 |
| Dutch Ophthalmic, USA | 1 | $166 |
| Amgen(2 entities) | 4 | $105 |
| Sun Pharmaceutical Industries Inc. | 4 | $97 |
| Ivantis, Inc | 4 | $92 |
| Harrow Eye, LLC | 3 | $90 |
| Carl Zeiss Meditec, Inc. | 1 | $50 |
| Shire North American Group Inc | 1 | $41 |
| Tarsus Pharmaceuticals, Inc. | 2 | $40 |
| Dompe US, Inc. | 1 | $23 |
| Genentech USA, Inc. | 1 | $19 |
| Ocular Therapeutix, Inc. | 1 | $17 |
| NEW World Medical,inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$143,715
- Rhopressa$5,921
- Rocklatan$5,666
- EYSUVIS$1,750
- VYZULTA$1,220
- CLARUS$912
- RESTASIS$750
- XEN$682
- LUMERA$501
- INVELTYS$450
- XEN GLAUCOMA TREATMENT SYSTEM$379
- OMNI(R) SURGICAL SYSTEM (US)$375
- iStent inject Trabecular Micro-Bypass Stent System$366
- XIIDRA$345
- SIMBRINZA$274
- TYRVAYA$267
- Tecnis IOL$217
- EVA, combined machine$166
- TISSUEBLUE$166
- MIEBO$145
How this compares
$173,367 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 843 | $415,211 |
| RocklatanNetarsudil Mesylat/Latanoprost | 495 | $248,599 |
| CombiganBrimonidine Tartrate/Timolol | 454 | $196,053 |
| XiidraLifitegrast | 170 | $177,249 |
| RestasisCyclosporine | 117 | $148,574 |
| RhopressaNetarsudil Mesylate | 241 | $112,222 |
| Alphagan PBrimonidine Tartrate | 127 | $63,784 |
| VyzultaLatanoprostene Bunod | 122 | $59,384 |
| XdemvyLotilaner | 31 | $57,550 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 231 | $44,981 |
| EysuvisLoteprednol Etabonate | 76 | $37,335 |
| Cyclosporine | 47 | $31,010 |
| Prednisolone Acetate | 583 | $29,803 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 116 | $26,247 |
| TyrvayaVarenicline Tartrate | 32 | $22,738 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $154,244 | $823,6221,541 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $6,093 | $360,821736 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $721 | $254,820317 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $40 | $57,55031 claims |
| Kala Pharmaceuticals, Inc.Eysuvis, Inveltys | $1,869 | $41,19389 claims |
| AlconSimbrinza, Azopt | $1,952 | $34,861135 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $391 | $22,73832 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $1,694 | $14,74657 claims |
| NovartisTravatan Z | $1,556 | $6,60013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in San Francisco
- Daniel SchwartzSan Francisco$8M
- Gaurav ShahSan Francisco$620K
- Shan LinSan Francisco$374K
- H TanakaSan Francisco$238K
- Jay StewartSan Francisco$219K
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.